News | July 10, 2013

Reliable Method Found to Detect Congenital Heart Disease for Babies in the Womb

Researchers analyzed 245 high-risk pregnant patients


July 10, 2013 — Researchers have announced the results of a five-year study that shows early fetal echocardiography provides reliable prenatal diagnosis of major congenital heart disease (CHD). First trimester screening looks very promising for detection of heart problems and increases the need for scheduling early and detailed cardiac evaluations.

“We were excited to find that the accuracy of prenatal cardiac screening was over 95.5 percent in our study,” said Elena Sinkovskaya, RDMS, RDCS, Ph.D., primary investigator and an assistant professor of obstetrics and gynecology at Eastern Virginia Medical School.

She and her colleagues analyzed 245 high-risk pregnant patients with prenatal and postnatal ultrasounds. The quality of images provided by the echocardiograms was sufficient to allow for a detailed evaluation of the fetal heart in the large majority of the fetuses scanned.

The study, “Fetal Cardiac Imaging in Early Pregnancy: Analysis of 254 Echocardiograms Performed Between 11+0 and 16+6 Weeks Gestation,” was presented as a poster at the 2013 American Society of Echocardiography (ASE) Annual Scientific Sessions.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now